Stonepine Capital Management LLC Makes New Investment in Savara Inc. $SVRA

Stonepine Capital Management LLC bought a new position in Savara Inc. (NASDAQ:SVRA) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 29,079 shares of the company’s stock, valued at approximately $81,000.

Other hedge funds have also bought and sold shares of the company. XTX Topco Ltd purchased a new position in Savara in the 4th quarter worth about $34,000. Ameriprise Financial Inc. purchased a new position in Savara in the 4th quarter worth about $37,000. Hsbc Holdings PLC purchased a new position in Savara in the 4th quarter worth about $48,000. Jump Financial LLC purchased a new position in Savara in the 4th quarter worth about $64,000. Finally, Brooklyn Investment Group purchased a new position in Savara in the 1st quarter worth about $65,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Oppenheimer boosted their target price on Savara from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, August 15th. Wells Fargo & Company reduced their price target on shares of Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Wednesday, May 28th. Guggenheim reaffirmed a “buy” rating and set a $8.00 price target (down previously from $9.00) on shares of Savara in a research report on Wednesday, May 28th. HC Wainwright raised shares of Savara from a “neutral” rating to a “buy” rating and upped their price target for the company from $2.00 to $5.00 in a research report on Friday, August 15th. Finally, Evercore ISI reduced their price target on shares of Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a research report on Wednesday, May 28th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Savara currently has a consensus rating of “Moderate Buy” and an average target price of $6.17.

Savara Price Performance

NASDAQ SVRA opened at $3.16 on Friday. Savara Inc. has a 52 week low of $1.89 and a 52 week high of $4.70. The firm has a market capitalization of $546.17 million, a P/E ratio of -6.32 and a beta of 0.40. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25. The company has a 50-day moving average price of $2.47 and a 200-day moving average price of $2.67.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Equities research analysts anticipate that Savara Inc. will post -0.45 earnings per share for the current year.

Insider Activity

In related news, Director Richard J. Hawkins acquired 48,225 shares of the business’s stock in a transaction that occurred on Friday, June 20th. The stock was bought at an average cost of $2.04 per share, for a total transaction of $98,379.00. Following the purchase, the director owned 115,466 shares in the company, valued at $235,550.64. The trade was a 71.72% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 5.33% of the company’s stock.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.